Overview of melanoma vaccines: active specific immunotherapy for melanoma patients.
Although a phase III trial has yet to show a statistically significant improvement in the disease-free or overall survival of melanoma patients receiving vaccine therapy, several phase II trials have shown enhanced disease-free and overall survival of patients who develop a humoral and/or cellular response to a melanoma vaccine. The challenge of active specific immunotherapy research is to determine which combination of humoral and cellular immune responses optimizes clinical outcome and how to monitor the immune response effectively. This review identifies key components of a successful melanoma vaccine, discusses new ways to modulate and stimulate the immune system, and summarizes some of the important clinical trials of active specific immunotherapy for patients with melanoma.
Ollila
D W
DW
The Roy E. Coats Research Laboratories, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California 90404, USA.
Kelley
M C
MC
Gammon
G
G
Morton
D L
DL
D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D016233:Immunotherapy, Active; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines